All In Biotech

Drug Trial Radar · NCT02577523

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H [ ] in Subjects With Advanced Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: May 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Dec 29, 2015

Primary completion

Dec 20, 2016

Study completion Jan 31, 2017

Sponsor

Lead sponsor
NeuroDerm Ltd.Industry
Sponsor type
Industry
First posted
Oct 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, parallel-group, rater-blinded, randomized clinical study in subjects with advanced PD investigating the efficacy, PK, safety and tolerability of continuous SC infusion of 2 dosing regimens of ND0612H, a solution of LD/CD delivered via a pump system as a continuous SC infusion, compared to standard oral LD/CD. After screening, subjects will undergo 1 day of standard oral LD/CD inpatient dosing followed by 2 days of inpatient treatment with 1 of 2 randomly allocated (1:1 randomization ratio) dosing regimens of ND0612H continuous SC infusion. Subjects will then continue on a maintenance dose of the assigned ND0612H dosing regimen for the next 25 days. A safety visit will be performed 4 weeks after the last SC administration of the study drug for a total of about 2.5 months of participation for each subject enrolled into the trial.

Conditions

  • Parkinson's Disease

Interventions

  • ND0612 (Levodopa/Carbidopa solution)Drug

    The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.

  • ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CDDrug

    The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Daily "OFF" TimeTime frame: Baseline to Day 28

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Northwestern University

    Chicago, Illinois

  • QUEST Research Institute

    Farmington Hills, Michigan

  • University of Cincinnati

    Cincinnati, Ohio

  • Medical University Innsbruck

    Innsbruck, Austria

  • Rabin Medical Center

    Petah Tikva, Israel

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • University Foundation

    Chieti, Italy

  • AOU Pisa

    Pisa, Italy

  • IRCCS San Raffaele Pisana

    Rome, Italy

  • Fondazione Ospedale San Camillo - I.R.C.C.S.

    Venice, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.